Ozempic vs Wegovy

Same molecule. Same manufacturer. Different approved use, different dose, and a difference that affects what your insurance will pay and what a company is allowed to tell you.

The short version

Ozempic is approved for type 2 diabetes. It is a once weekly semaglutide injection used to improve blood sugar control in adults with type 2 diabetes.

Wegovy is approved for chronic weight management, at a higher maximum dose, for adults meeting certain weight criteria.

Both contain semaglutide. Neither is a version of the other.

Why almost every comparison page gets this wrong

Ozempic is the far more searched name. It became the shorthand for this entire class of medicine, to the point where people say "ozempic" the way they say "hoover."

The result is that a lot of content compares things to Ozempic when the correct comparison is Wegovy. If you are taking semaglutide to lose weight, the approved product that matches what you are doing is Wegovy.

This matters practically in two places.

Coverage. Plans frequently cover a diabetes medicine and not a weight management one, or apply different prior authorisation rules to each. Which brand is on the prescription can change what you pay.

Comparison against compounded products. Compounded semaglutide is often marketed against Ozempic because it is the recognised name. The dose and schedule being copied may be neither product's.

Off-label prescribing, plainly

A clinician may lawfully prescribe an approved medicine for something outside its approved use. That is called off-label prescribing, it is common across all of medicine, and it is not a loophole.

What it does mean is that the evidence supporting that specific use may be thinner, and that your insurer may decline to pay.

The dose difference

The two products use different dosing schedules, with Wegovy going to a higher maximum for weight management. This is one reason they are not interchangeable, and one reason a compounded product copying "semaglutide" without specifying which schedule it follows is telling you very little.

What the trials showed

The weight management evidence belongs to the higher dose. In its main obesity trial, semaglutide 2.4 mg produced average weight loss of 14.9 percent against 2.4 percent on placebo, with 50.5 percent of participants reaching at least 15 percent weight loss.

Semaglutide also has cardiovascular outcome evidence. In the SELECT trial it reduced a combined endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke, hazard ratio 0.80, 95 percent confidence interval 0.72 to 0.90.

Side effects are the same family

Both are semaglutide, so the side effect profile is the same class of thing, dominated by gastrointestinal events during dose escalation. Across GLP-1 trials, gastrointestinal events were reported by 47 to 84 percent of participants against 13 to 63 percent on placebo.

Both carry a boxed warning for thyroid C-cell tumours and are contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Cost in 2026

CMS names Wegovy, in injection and tablet form, among the products available under the Medicare GLP-1 Bridge at fifty dollars a month for eligible beneficiaries, running 1 July 2026 to 31 December 2027. Both products became available at reduced cash prices through the federal direct purchasing channel launched in early 2026.

Coverage for a diabetes indication and coverage for a weight management indication are still handled differently by many plans, so it is worth asking about your specific product rather than the molecule.

What to ask

• Which product am I actually being prescribed, and for which approved use?
• If it is off-label, will my plan cover it?
• What dose and schedule am I on, and does it match the approved one for my situation?
• Am I eligible for the Medicare GLP-1 Bridge?

Sources

• Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021
• Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 2023
• Efficacy and safety of GLP-1 receptor agonists for weight management, systematic review and meta-analysis, 2025
• Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge
• FDA, "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs"

How we verify: see /how-we-verify.

Keep reading

The two leading approved weight management products compared, at /guides/wegovy-vs-zepbound.

Why compounded semaglutide is not the same as either, at /guides/compounded-semaglutide-vs-ozempic.